Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker

Next Previous
Trial Profile

A Randomized Phase II Study of Preoperative Cisplatin Versus Paclitaxel in Patients With Triple Negative Breast Cancer: Evaluating the Homologous Recombination Deficiency (HRD) Biomarker

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Jul 2024

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cisplatin (Primary) ; Paclitaxel (Primary) ; Cyclophosphamide; Doxorubicin
  • Indications Early breast cancer; Triple negative breast cancer
  • Focus Therapeutic Use

Most Recent Events

  • 04 Jun 2024 Results of Correlation of TILs indices generated by visual review and digital computational algorithm with outcomes from preoperative chemotherapy for TNBC , presented at the 60th Annual Meeting of the American Society of Clinical Oncology
  • 30 May 2024 According to a 4D Path media release, the company will present new clinical data from this trial highlighting efficacy of the Q-Plasia OncoReader (QPOR) Platform will be presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting, May 31 - June 4, 2024.
  • 15 Jun 2023 Status changed from discontinued to completed.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top